Researchers tested dupilumab on various patient groups with atopic dermatitis (AD) to see how this treatment impacted all-cause and AD-related hospitalization rates.
Researchers tested dupilumab on various patient groups with atopic dermatitis (AD) to see how this treatment impacted all-cause and AD-related hospitalization rates.